$JNJ

Global cytokines market projected to grow from $95.32B (2025) to $174.53B (2032) at 9.02% CAGR, driven by manufacturing advances and strategic partnerships.

Escalating Middle East tensions drive investors to defensive stocks including defense contractors, energy majors, consumer staples, and utilities offering stability and income.

AbbVie's Skyrizi achieved 55% remission rate in Crohn's patients versus 30% placebo, strengthening competitive positioning against Johnson & Johnson's Tremfya.

Global antibiotics market to grow from USD 55.60B in 2025 to USD 70.64B by 2031 at 4.07% CAGR, driven by antimicrobial resistance and innovation.

Colorectal cancer deaths surge among Americans under 50, becoming the leading cancer killer in this age group. An awareness campaign installs 27,000 blue flags on the National Mall.

BMS's Sotyktu shows promise for psoriatic arthritis among one-third of surveyed rheumatologists, but analysts expect modest market capture ahead of March 2026 FDA decision.

Medical device cleaning market projected to nearly double to $3.74B by 2032, driven by stricter infection control regulations and shift toward reusable devices in healthcare.

Advanced drug delivery systems market projected to grow from $299.6B (2025) to $487.4B (2030), driven by chronic diseases, nanotechnology breakthroughs, and oncology applications.

J&J stock hits record highs with 14% monthly returns, outperforming tech due to stable dividends, strong cash flow, and lower volatility amid market uncertainty.

Alpine Capital Research increased its Arrow Electronics stake to 5.9% of AUM ($379M) in Q4 2025, reflecting confidence in the tech distributor's strong operational momentum and financial performance.

Vanguard value-focused ETFs outperform flat S&P 500 as sector rotation into financials, industrials, and energy accelerates, offering higher dividend yields.

Johnson & Johnson maintains Dividend King status with 63 consecutive years of dividend increases, offering stable income through its diversified healthcare business and AAA credit rating.

J&J plans to divest DePuy Synthes orthopedics unit valued at $20-28 billion. Private equity firms are negotiating potential acquisition bids as part of J&J's portfolio restructuring strategy.

Long-acting HIV injectable therapy significantly outperforms daily pills in Phase 3 trial, showing lower failure rates and improved outcomes for patients with adherence challenges.

FDA grants J&J's Rybrevant Faspro breakthrough designation for HPV-negative head and neck cancer, potentially accelerating patient access to this new treatment option.

Four prominent trial attorneys—Placitella, Rosner, Eglet, and Kline—inducted into 2026 Trial Lawyer Hall of Fame for their decades of litigation experience and significant courtroom achievements.

Scar treatment market to double to $56.3B by 2033, driven by advanced minimally invasive procedures and rising cosmetic demand globally.

J&J's lung cancer therapy Rybrevant Faspro gains FDA approval for accelerated monthly dosing, maintaining efficacy while improving patient convenience and reducing treatment burden.

Hemostasis products market expected to grow from $1.94B to $3.28B by 2035, driven by increased surgeries and trauma cases requiring advanced bleeding control solutions.

Fibrin sealant market to double from $1.60B to $3.57B by 2035, driven by surgical demand and minimally invasive techniques despite accessibility challenges in developing regions.